Eli Lilly to buy Kelonia in $7B biotech acquisition

Pharmaceutical giant Eli Lilly agreed to acquire Kelonia, a clinical-stage gene editing company, for $7B. The acquisition adds Kelonia's in vivo gene correction platform to Lilly's pipeline — potentially enabling one-time treatments for inherited metabolic diseases. Backers report a 70x return.